Sep 252012
 

As we’ve said before, and throughout our website, for publicly traded life sciences companies, having at-the-market financing in the toolkit just makes sense. ATMs deliver control over the timing and amount of stock that reaches the market, giving life sciences organizations the flexibility to fund a clinical trial, make leveraged investments, ride the waves of an industry-specific event, and anything else that benefits from access to measured amounts of equity capital over time.

Here’s another benefit: ATM offerings provide the lowest cost of capital, too.

Life Science banking deals

Calculations

  • Deal timeframe: 1/1/2012 – 9/25/2012
  • Filter by issuer market cap: $30 million – $7 billion
  • Warrants cost calculated using Black Scholes European option pricing model
  • Market discount determined by calculating the percent change from the deal price and the stock price one day prior to deal announcement

Jul 192012
 

Strategic CFOs in the life sciences industry are increasingly employing ATMs because they enable companies to better control the financing process and the relatively low cost compared to more traditional follow-on financing vehicles.

Med City: Common Misunderstandings of an Emerging Financing Vehicle: At-the-Market Offerings